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Vaginally delivered microbicides are being developed to offer women self-initiated protection against transmission of sexually
transmitted infections such as Chlamydia trachomatis. A small molecule, DS-96, rationally designed for high affinity to Esche-
richia coli lipid A, was previously demonstrated to bind and neutralize lipopolysaccharide (LPS) from a wide variety of Gram-
negative bacteria (D. Sil et al., Antimicrob. Agents Chemother. 51:2811–2819, 2007, doi:10.1128/AAC.00200-07). Aside from the
lack of the repeating O antigen, chlamydial lipooligosaccharide (LOS) shares general molecular architecture features with E. coli
LPS. Importantly, the portion of lipid A where the interaction with DS-96 is expected to take place is well conserved between the
two organisms, leading to the hypothesis that DS-96 inhibits Chlamydia infection by binding to LOS and compromising the
function. In this study, antichlamydial activity of DS-96 was examined in cell culture. DS-96 inhibited the intercellular growth of
Chlamydia in a dose-dependent manner and offered a high level of inhibition at a relatively low concentration (8 M). The data
also revealed that infectious elementary bodies (EBs) were predominantly blocked at the attachment step, as indicated by the
reduced number of EBs associated with the host cell surface following pretreatment. Of those EBs that were capable of attach-
ment, the vast majority was unable to gain entry into the host cell. Inhibition of EB attachment and entry by DS-96 suggests that
Chlamydia LOS is critical to these processes during the developmental cycle. Importantly, given the low association of host tox-
icity previously reported by Sil et al., DS-96 is expected to perform well in animal studies as an active antichlamydial compound
in a vaginal microbicide.
With over 1.3 million new cases reported each year, infectiondue to Chlamydia trachomatis is the most commonly re-
ported infection in the United States (1). Although C. trachomatis
infections are highly treatable with appropriate antibiotics upon
detection, the vast majority (70 to 90%) of infections in women
are undiagnosed due to the high asymptomatic rate and progress
untreated (2). Untreated C. trachomatis infections can result in
severe long-term consequences in women, including pelvic in-
flammatory disease (PID), ectopic pregnancy, and infertility (3).
In addition, C. trachomatis infections have been linked to in-
creased risks of acquisition and transmission of HIV (4). These
concerns associated with C. trachomatis infection highlight the
urgent need for novel preventative strategies; however, despite
ongoing efforts, protective vaccines against Chlamydia currently
are unavailable for clinical use. In the absence of effective vaccines,
one alternative approach for prevention is the use of vaginally
delivered topical microbicides, which offer the possibility of a fe-
male-controlled strategy for the prevention of sexually transmit-
ted infections at the time of initial exposure.
Blocking infection in an early stage of pathogenicity (i.e., ad-
herence and entry) before bacteria gain access to the host is a
desirable preventative approach, as often evidenced in the efforts
to produce sterile immunity in vaccine development. Bacterial
surface molecules are potential targets for this purpose, because
they often play essential roles in establishing a productive infec-
tion. One such molecule is lipopolysaccharide (LPS) of Gram-
negative bacteria. LPS is a major constituent of the outer mem-
brane and plays a crucial role for the survival of the organisms by
maintaining membrane integrity and providing a permeability
barrier (5–7). LPS has also been suggested to play a role in bacterial
adhesion as well as being a prominent virulence-determining fac-
tor for several Gram-negative organisms, and it may be a target
molecule in the development of antimicrobial agents (8–11).
A small molecule, DS-96, a synthetic alkylpolyamine, was pre-
viously developed to neutralize the endotoxicity of LPS in the
pathogenesis of Gram-negative septic shock (Fig. 1A) (12). The
molecule was rationally designed based on a nuclear magnetic
resonance (NMR)-derived model of the interaction between Esch-
erichia coli LPS and the antibiotic polymyxin B (PMB) (12–15).
The cationic polypeptide antibiotic PMB is well known for its
ability to bind to and neutralize the anionic lipid A moiety, which
elicits a strong immune response when present in systemic circu-
lation (16). The pharmacophore necessary for optimum binding
and neutralization of LPS was determined through the model and
used to synthesize various polycationic amphiphiles with a sperm-
ine backbone, and eventually it led to the discovery of a novel
alkylpolyamine, DS-96 (12). In their study, Sil et al. demonstrated
that DS-96 was capable of binding to LPS with high affinity and
neutralized LPS endotoxicity of a variety of Gram-negative bacte-
ria with potency indistinguishable from that of PMB (12). Impor-
tantly, daily administration of DS-96 at concentrations 10-fold
higher than the fully protective dose resulted in no detectable tox-
icity in a mouse study (12). In Chlamydia, PMB treatment of the
organism has been demonstrated to significantly decrease infec-
tivity in cell culture infection (17–19) and also to impair the bac-
terial membrane integrity (20). Despite its effectiveness, clinical
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use of unmodified PMB is limited due to the associated side effects
on the eukaryotic hosts (21).
C. trachomatis, like many other nonenteric mucosal pathogens,
possesses lipooligosaccharide (LOS) rather than LPS in its outer
membrane. Chlamydial LOS differs from a typical LPS in that it
consists of a trisaccharide core of 3-deoxy-D-manno-2-octulopy-
ranosylonic acid (Kdo) rather than disaccharide in LPS, and it
lacks the repeating O-antigen polysaccharide side chain, similar to
rough enterobacterial LPS (22). Nonetheless, LOS and LPS share a
conserved bisphosphorylated glucosamine backbone of lipid A at
which interaction with PMB takes places. In contrast to enteric
bacteria, chlamydial lipid A has been shown to exhibit low endo-
toxicity, reportedly due to the lower number of hydrocarbons and
the longer chain length (23, 24). In addition, while LPS is an im-
portant structural component for the membrane integrity of
Gram-negative bacteria, the outer membrane of the infectious,
extracellular form of Chlamydia is highly disulfide cross-linking of
cysteine-rich proteins, which is expected to provide structural ri-
gidity and stability (25, 26).
While numerous studies have reported on the antigenic and
immunogenic properties of Chlamydia LOS, knowledge concern-
ing the biological functions of LOS in the virulence-defining bi-
phasic developmental cycle and pathogenesis of Chlamydia is lim-
ited. The developmental cycle of these obligate intracellular
bacteria begins with the attachment of the infectious but metabol-
ically inert elementary body (EB) to the surface of nonphagocytic
epithelial cells. This attachment is a two-step process involving the
initial reversible electrostatic interaction with glycosaminoglycans
followed by a more specific irreversible binding to putative cell
surface receptors (27). Following attachment, the EB induces its
own uptake by initiating a signal transduction cascade of the host
cell that leads to recruitment and reorganization of the actin cyto-
skeleton at the site of attachment (28). Once inside the host cell,
the EB converts into a larger metabolically active reticulate body
(RB) which replicates by binary fission within a membrane-bound
vacuole, termed inclusion. After several rounds of replication, RBs
asynchronously transform into EBs and are released by host cell
lysis or extrusion (29). Recently, Nguyen et al. used a chemical
inhibitor of lipid A biosynthesis to demonstrate the crucial role of
chlamydial LOS in proper conversion of RBs into infectious EBs
(30). Interestingly, inhibition of LOS synthesis had little effect on
RB replication, highlighting the importance of LOS in EB func-
tion. The biological significance of LOS during early infectious
stages of the developmental cycle, such as binding and entry, re-
mains to be elucidated.
Given the demonstrated high affinity of DS-96 for LPS of other
Gram-negative bacteria and conserved structural features be-
tween LPS and chlamydial LOS, it was hypothesized that DS-96
inhibits Chlamydia infection by binding to the lipid A moiety and
compromising the function of LOS that is crucial during the de-
velopmental cycle. To study this hypothesis, the inhibitory activity
FIG 1 DS-96 exhibits inhibition of C. trachomatis infection in a dose-dependent manner. (A) Chemical structure of DS-96. (B) C. trachomatis EBs were treated
with various concentrations of DS-96 (0 to 16 M) or DMSO (mock treatment) for an hour prior to infection. L929 cells were infected with pretreated EBs and
cultured for 24 h before fixation and immunostaining. Chlamydia was stained with anti-MOMP antibody (green), and host cells were counterstained with DAPI
(nuclei; blue) and Evan’s blue (cytoplasm; red). (C) Inhibition of inclusion formation among the samples treated with various concentrations of DS-96 was
quantified 24 hpi using the automated enumeration method iBAChIE (32). Percent inhibition was determined based on the number of inclusion-positive cells
in DS-96-treated samples relative to DMSO-treated samples. Error bars indicate standard deviations from the triplicate samples. The concentration at which 50%
of infection is inhibited (IC50) was calculated to be 5.1 M using a linear regression analysis in the concentration range of 1 to 8 M. An asterisk indicates a
significant difference from the untreated control (P  0.001 by Student’s t test). (D) Cytotoxic effect of DS-96 on L929 cells was examined using a redox indicator,
alamarBlue. The concentration of DS-96 that decreased the reducing capability to 50% of that of DMSO-treated cells (CC50) was calculated to be 17.5 M using
a linear regression analysis in the concentration range of 6 to 22 M.
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of DS-96 during various stages of C. trachomatis infection was
examined in cell culture.
MATERIALS AND METHODS
Bacteria and cell culture. C. trachomatis lymphogranuloma venereum
(LGV) serovar L2/434/Bu EBs were purified from infected L929 cells using
a 30% Renografin density gradient and stored in sucrose-phosphate-glu-
tamate (SPG) at 80°C until use, as previously described (31). L929 cells
were routinely cultured in RPMI 1640 culture medium (Mediatech, Inc.,
Manassas, VA) supplemented with 5% fetal bovine serum (FBS) (Thermo
Fisher Scientific, Liverpool, NY) and 10 g/ml gentamicin (MP Biomedi-
cals, Santa Ana, CA) at 37°C in a humidified atmosphere of 5% CO2. C.
trachomatis serovar D/UW-3/Cx was isolated from infected HeLa 229
cells, and C. muridarum strain Nigg was purified from infected L929 cells
as described previously (31).
Compound preparation. DS-96 was a kind gift from Sunil David
(University of Kansas) and was obtained in powder form. The compound
was dissolved in 100% dimethylsulfoxide (DMSO) to a stock concentra-
tion of 1 mM and stored at 4°C. Heparan sulfate (HS; Sigma-Aldrich, St.
Louis, MO) was obtained in powder form, dissolved in deionized water to
a stock concentration of 500 g/ml, and stored at 80°C.
alamarBlue cytotoxicity assay. L929 mouse fibroblast cells were
plated in a 96-well plate (Bioexpress, Kaysville, UT) at a density of 8  104
cells/ml, 200 l/well, and incubated overnight. DS-96 was serially diluted
in Hanks’ buffered salt solution (HBSS; Mediatech, Inc., Holly Hill, FL)
and incubated for 2 h at room temperature. Following the incubation
period, cells were washed once with HBSS and supplemented with RPMI
1640 culture medium without phenol red, and 10% (vol/vol) alamarBlue
reagent (Life Technologies, Grand Island, NY) was added. The samples
were incubated at 37°C for 24 h. After 24 h, the absorbance was measured
in a PowerWave microplate spectrophotometer (BioTek, Winooski, VT)
at 570 nm (reduced) and 600 nm (oxidized) with KC4 data collection and
analysis software (BioTek, Winooski, VT). The results were expressed as
the percentage of alamarBlue reduced by cells in the presence of DS-96
relative to alamarBlue reduced by control cells in the absence of the com-
pound, using a formula provided by the manufacturer: [(εox)2A1 
(εox)1A2]/[(εox)2A=1  (εox)1A=2]  100, where εox is the molar
extinction coefficient of the alamarBlue oxidized form, A is the absor-
bance of test wells, A= is the absorbance of the positive-control well (un-
treated), 1 is 570 nm, and 2 is 600 nm. A linear regression equation
(y  4.1979x  123.51, where y is viability of host cells and x is DS-96
concentration) was generated in the concentration range of 6 to 22 M
using Excel. The 50% cytotoxic concentration (CC50) was calculated us-
ing this equation.
Chlamydia infection and inhibition assays. Purified C. trachomatis
L2 EBs were diluted to the appropriate concentrations in HBSS. DS-96 or
DMSO, as a mock treatment control, was diluted in either HBSS alone or
HBSS containing diluted EBs to the appropriate concentrations according
to treatment type. The mixtures of bacteria and compound were incu-
bated for an hour at room temperature. Following this incubation, the
mixtures were added to a monolayer of cells. Cells were incubated at room
temperature for 2 h. For the centrifugation-assisted infection, the samples
were centrifuged at 900  g for 1 h. After the infection period, cells were
washed once with HBSS, fresh culture medium was added, and the solu-
tion was incubated at 37°C in an atmosphere of 5% CO2. For the treat-
ment of host cells, diluted DS-96 or DMSO in HBSS containing no bac-
teria was transferred to L929 cell monolayers and incubated for an hour at
room temperature. Following the incubation period, the compound was
removed and cells were washed before bacteria were added. For other
treatment conditions, bacteria were pretreated or DS-96 was added to
culture medium at the indicated time period. Twenty-four hours postin-
fection (hpi), cells were washed once with HBSS and fixed with 100%
methanol for 10 min at room temperature. Samples were kept in phos-
phate-buffered saline (PBS) at 4°C until the time of analysis. To calculate
the 50% inhibitory concentration (IC50) for the dose-dependent inhibi-
tion analysis (Fig. 1C), a linear regression equation (y  12.624x  16.326,
where y is inhibition level and x is the DS-96 concentration) was generated
in the concentration range of 1 to 8 M using Excel.
Immunofluorescence microscopy. Following fixation, samples were
stained with a MicroTrack C. trachomatis culture confirmation test (Syva
Co., Palo Alto, CA) diluted to 1:40 in PBS for an hour in the dark, followed
by a 5-min stain with 1 g/ml 4=,6-diamidino-2-phenylindole (DAPI) in
PBS. DAPI was removed, and 90% (vol/vol) glycerol in PBS was added to
prevent rapid fading of fluorescence during analysis. For manual analysis,
plates were stored in the dark at 4°C until imaging. Samples were visual-
ized using an Olympus ix71 inverted fluorescence microscope (Center
Valley, PA) with a 40 objective and 0.55 numerical aperture. Images
were captured using a QImaging QICAM digital camera, 12-bit Mono
Fast 1394 cooled camera, and QCapture Suite software, version 3.1.3.5
(QImaging Corp., Surrey, BC, Canada). Image-based automated quanti-
fication using CellProfier and CellProfiler Analyst (iBAChIE) was per-
formed as described previously (32).
Antibody staining of C. trachomatis EBs. For staining of C. tracho-
matis EBs with anti-LOS antibody, EBs were incubated with 8 M DS-96
or the equivalent dilution of DMSO as a control at room temperature for
pretreatment. After 1 h, 300 l of the pretreated bacteria was transferred
into 8-well -chamber slides (ibidi, Verona, WI). Bacteria were allowed to
settle and adhere to the bottom of the plate at room temperature for 1 h.
The liquid was aspirated, and bacterial samples were fixed with 100%
methanol for 10 min. For immunofluorescence staining, one set of sam-
ples was stained with monoclonal anti-LOS antibody (1683; ViroStat)
diluted 1:500 in PBS at room temperature for 1 h, washed with PBS,
incubated with secondary goat anti-mouse Alexa Fluor 488 (Invitrogen,
Carlsbad, CA), and counterstained with 1 g/ml DAPI in PBS for 5 min.
A parallel set of samples was stained with primary goat anti-MOMP anti-
body (1621; ViroStat) diluted 1:500 in PBS for an hour, washed with PBS,
incubated with secondary donkey anti-goat Alexa Fluor 568 (Invitrogen,
Carlsbad, CA) at 1:1,000 dilution for an hour, and stained for 5 min with
1 g/ml DAPI in PBS. Samples were viewed with an Olympus ix71 in-
verted fluorescence microscope (Center Valley, PA) with a 40 objective
and 0.55 numerical aperture. Images were captured using a QImaging
QICAM digital camera, 12-bit Mono Fast 1394 cooled camera, and
QCapture Suite software, version 3.1.3.5 (QImaging Corp., Surrey,
BC, Canada).
Attachment assay. Purified C. trachomatis L2 EBs were diluted in
HBSS, and DS-96 was added to a final concentration of 8 M for pretreat-
ment of the bacteria for an hour at room temperature. An equivalent
dilution of DMSO mock treatment was used as a negative control, and 500
g/ml HS was used as a positive control for inhibition of chlamydial
attachment. L929 cells were infected with compound-treated EBs and
incubated at 4°C for an hour. Following infection, cells were washed three
times with cold HBSS to remove nonspecifically bound EBs, fixed with
100% methanol, and stained with a MicroTrack C. trachomatis culture
confirmation kit. Images were captured using SlideBook (Intelligent Im-
aging Innovations, Inc., Denver, CO) software and an Olympus IX81
inverted microscope (Center Valley, PA) equipped with a 1.45-numeri-
cal-aperture, oil-immersion 100 objective and a Hamamatsu electron
microscope charge-coupled device (EM-CCD) camera.
Entry assay. Purified C. trachomatis L2 EBs were diluted in HBSS and
incubated with 8 M DS-96 at room temperature for an hour for pretreat-
ment. An equivalent dilution of DMSO mock treatment was used as a
negative control. The inocula were added to L929 cells and incubated for
2 h at room temperature. Following the incubation period, the inocula
were removed, cells were washed, and fresh culture media were added.
Infected cells were incubated at 37°C for 3 h to allow sufficient time for
bacterial attachment and entry. At 3 hpi, culture medium was removed
and cells were washed once with PBS. Differential staining was performed
to distinguish the bacteria that remained extracellular from those that
gained entry into the host cells. To stain the extracellular bacteria, the cells
were incubated with primary goat anti-MOMP antibody (1621; ViroStat)
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diluted 1:500 in PBS for an hour at room temperature prior to permeabi-
lization of host cells. The cells were washed three times with PBS, fixed,
and permeabilized with 100% methanol for 10 min at room temperature.
The cells were washed once with PBS to remove methanol and incubated
with secondary donkey anti-goat Alexa Fluor 568 (Invitrogen, Carlsbad,
CA) at a 1:1,000 dilution for an hour. Following three washes with PBS,
the cells were incubated with primary mouse anti-Chlamydia antibody
(ab21019; Abcam) diluted 1:500 for an hour at room temperature, washed
three times with PBS, and incubated with secondary goat anti-mouse
Alexa Fluor 488 (Invitrogen, Carlsbad, CA). Following three washes with
PBS, cells were incubated with 1 g/ml DAPI in PBS for 5 min to label host
cell nuclei. Images were captured using SlideBook (Intelligent Imaging
Innovations, Inc., Denver, CO) software and an Olympus IX81 inverted
microscope (Center Valley, PA) equipped with a 1.45-numerical-aper-
ture, oil-immersion 100 objective and a Hamamatsu EM-CCD camera.
RESULTS
DS-96 inhibits Chlamydia infection in a dose-dependent man-
ner. To begin examining the effect of DS-96 on Chlamydia infec-
tion, C. trachomatis L2 EBs were pretreated with various concen-
trations of the compound, ranging from 0 to 16 M. The standard
procedure for Chlamydia infection of cell culture consists of a 2-h
infection of eukaryotic cell monolayers at room temperature to
facilitate attachment. This is followed by washing to remove un-
bound bacteria and then placement at 37°C to fully enable chla-
mydial entry. In the inhibition assay, EBs were preincubated with
DS-96 for an hour before addition to cell monolayers. This was to
allow sufficient time for the interaction to take place between
DS-96 and the target molecule, chlamydial LOS, prior to exposure
of EBs to host cells. Exposure of infectious EBs to concentrations
of DS-96 greater than 1 M resulted in inhibition of chlamydial
growth, as indicated by a decrease in the percentage of host cells
containing inclusions after 24 h (Fig. 1B and C). Over a concen-
tration range of 0 to 16 M, a dose-dependent inhibition of
infection was observed with greater than 80% inhibition at 8 M
relative to the DMSO mock-treated culture. More than a doubling
in the number of infected cells was observed as the DS-96 concen-
tration was reduced from 8 to 4 M (83.9% and 31.3% inhibition,
respectively). The 50% inhibitory concentration (IC50) was calcu-
lated to be 5.3 M using a linear regression analysis in the concen-
tration range of 1 to 8 M. Interestingly, the sizes of individual
inclusions after 4 M DS-96 treatment were much smaller than
those of DMSO mock-treated sample (Fig. 1B), although this was
not quantified. This observation may be explained by the ability of
multiple EBs to infect a single cell and form much larger inclu-
sions, suggesting that fewer bacteria, on average, infected individ-
ual cells as a result of treatment with 4 M DS-96. In concert with
this hypothesis, inhibition levels observed between treatments
with 2 and 4 M DS-96 are similar; however, the inclusions at 2
M are larger and similar in size to those from DMSO-treated
samples. An alternative hypothesis is that DS-96 is slowing Chla-
mydia entry and/or developmental progression (e.g., replication),
resulting in smaller inclusions at certain concentrations. As Chla-
mydia is an obligate intracellular organism, it is crucial to ensure
that the observed inhibitory effect is due to the direct action of the
compound on Chlamydia rather than an indirect cytotoxic effect
on the host cell. Although no detectable toxicity was reported in
the murine model (12), DS-96 has not been reported previously in
cell culture. To evaluate the possible cytotoxicity of DS-96, a resa-
zurin-based assay (alamarBlue) was used to quantitatively assess
host cell metabolic activity following exposure to DS-96 (Fig. 1D).
This assay indicated that no significant cytotoxicity was observed
following exposure of DS-96 concentrations up to 8 M. At 16
M, the reducing capability of the host cell decreased to approx-
imately 60% of the untreated cells, which is consistent with host
cell rounding evident at 16 M treatment by microscopy (Fig.
1B). The 50% cytotoxic concentration (CC50) was calculated to be
17.0 M using a linear regression analysis in the concentration
range of 8 to 22 M. Based on the inhibitory effect and absence of
cytotoxicity at 8 M, this concentration was used for subsequent
studies.
DS-96 blocks the early events of the chlamydial developmen-
tal cycle. In order to better understand the underlying inhibitory
mechanism of DS-96, infected samples were treated with DS-96 at
different time periods during the developmental cycle, and Chla-
mydia growth was examined. When infected cells were treated
with DS-96 after bacteria were allowed to bind and begin entering
host cells, no significant effect on bacterial growth was observed
(data not shown). This suggests that DS-96 is membrane imper-
meable and, consequently, does not have access to the bacteria
once they are internalized into host cells. It could also indicate that
LOS is not essential once Chlamydia has gained access to the cell
and begun replicating. Therefore, the effect of DS-96 treatment
prior to the internalization of EBs was examined further (Fig. 2).
The treatment conditions included pretreatment of EBs for an
hour prior to addition to host cells, coincubation of DS-96 and
EBs with the host cell, and addition of the compound after EBs
were allowed to incubate with host cells (Fig. 2A). As Chlamydia
relies on the host cell for survival and replication, it was also im-
portant to ensure that DS-96 exposure to the host cell does not
perturb the cell and indirectly affect Chlamydia infectious pro-
cesses. Therefore, the host cells were pretreated with DS-96 for an
hour prior to incubation with the bacteria. As expected, the com-
pound was most effective in inhibiting Chlamydia infection when
bacteria were pretreated prior to infection (95.5%) (Fig. 2B).
When DS-96 and the bacteria were simultaneously added to the
cells (coincubation), the level of inhibition was decreased to
55.4%, indicating that the compound requires sufficient time to
establish an interaction with its target. When compound was
added after EBs had been incubated with host cells for 2 h, DS-96
exhibited no inhibitory effect on Chlamydia growth, supporting
the earlier observation that the compound may be unable to cross
the eukaryotic cell membrane. Pretreatment of host cells prior to
infection resulted in only a minimum level of inhibition (8.6%).
Together, these observations support that DS-96 blocks Chla-
mydia infection during the early stages of the developmental cycle,
specifically prior to chlamydial entry into the host cell.
DS-96 treatment impairs Chlamydia attachment and entry.
To determine more specifically which steps of the developmental
cycle were blocked by DS-96, attachment of Chlamydia to the host
cell was examined. C. trachomatis EBs were pretreated with DS-96
for an hour prior to infection and then given sufficient time (1 h)
to adhere to L929 cells at 4°C. After inoculum was removed and
cells were washed to remove the unbound bacteria, adherence of
EBs was qualitatively examined by immunofluorescence micros-
copy (Fig. 3). Heparan sulfate, as a highly negatively charged poly-
saccharide, is known to block Chlamydia adhesion to the target
cell in vitro by charge repulsion (33–37) and served as a positive
control for an inhibitor of Chlamydia adhesion in this study. In
the untreated sample (DMSO), an average of 15 to 20 EBs ap-
peared to be associated with the host cell surface (Fig. 3). As ex-
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pected, bacterial adhesion was blocked when EBs were pretreated
with heparan sulfate prior to infection. In samples pretreated with
DS-96, inhibition was observed as a decrease in the number of EBs
associated with the host cell. However, unlike that with heparan
sulfate, DS-96 treatment did not result in complete prevention of
bacterial adhesion; rather, the treatment decreased the number of
bacteria bound to a single cell by approximately 70%, with 2 to 5
EBs per cell remaining bound to the cell surface. This observation
was striking, given that 8 M DS-96 consistently resulted in high
levels of inhibition (greater than 85%) of inclusion formation
throughout our study. This result indicated that the majority of
EBs that remained bound to the host cell in the presence of the
compound still was unable to form productive inclusions.
One possible explanation for this observation is that DS-96
blocked postattachment events in addition to bacterial adhesion.
To investigate this possibility, entry of Chlamydia into the host cell
was examined. Similar to the attachment assay, EBs pretreated
with DS-96 or mock-treated (DMSO) EBs were allowed sufficient
time (4 h) to attach and enter the host cell. Differential immuno-
fluorescent staining was performed to discriminate between the
internalized bacteria and those remaining on the surface of the
host cell, and the samples were assessed by confocal microscopy
(Fig. 4A). Two subsequent staining steps were performed before
and after permeabilization of the host cell membrane to achieve
labeling of the extracellular bacteria with red fluorophore and
total bacteria with green fluorophore. In the representative images
shown in Fig. 4A, the majority of EBs in mock-treated sample
appeared green, indicating that these EBs had been internalized.
When pretreated with DS-96, consistent with the observation in
the attachment assay, bacterial adhesion was significantly de-
creased, as indicated by a decrease in the number of total EBs
associated with the host cell. In contrast to the mock-treated sam-
ple, EBs associated with the host cell in DS-96-treated samples
were costained and appeared yellow, indicating that these EBs
remained extracellular. Quantification of the number of the extra-
cellular and total EBs revealed that pretreatment of the bacteria
with DS-96 resulted in a drastic decrease in the percentage of
internalized EBs from 86.3% in mock-treated samples to 2.6% in
DS-96 treated samples (Fig. 4B). These findings demonstrate that
DS-96 blocks entry of C. trachomatis into host cells as well as
blocking adherence.
The effect of DS-96 on centrifugation-assisted infection.
Since the first report by Weiss and Dressler (38), it has been known
that centrifugation of the chlamydial inoculum onto host cell
monolayers enhances infectivity, although the degree of enhance-
ment varies among different species and serovars. The means by
which centrifugation enhances Chlamydia infectivity are not fully
understood; however, centrifugation is thought to override bind-
ing and entry mechanisms and greatly enhance absorption of the
bacteria (34). Interestingly, it has been reported that the inhibitory
effect of neutralizing antibody and heparan sulfate against Chla-
mydia is overcome by centrifugation (39). To examine whether
DS-96 was merely inhibiting binding and entry or also having a
further effect, such as inactivation of EBs, an inhibition assay was
performed with static and centrifugation-assisted infection (Fig.
5). In the presence of heparan sulfate, static infection resulted in
92.9% inhibition in Chlamydia growth. However, this inhibition
was overcome when inoculation was facilitated by centrifugation
(900  g for 1 h). In comparison, when C. trachomatis EBs were
FIG 2 DS-96 inhibits initial stages of Chlamydia infection through interaction
with EBs rather than host cells. Infection levels were compared among various
treatment conditions of DS-96 (8 M). (A) Treatment conditions. Row a,
pretreatment of bacteria; row b, coincubation of bacteria and host cell; row c,
addition of DS-96 to the infected culture 0 to 2 hpi; row d, pretreatment of the
host cell. (B) Inhibition of inclusion formation relative to mock-treated sam-
ples was quantified for each treatment condition 24 hpi using iBAChIE (32).
The percentage of infection was calculated based on the number of inclusion-
positive cells in DS-96-treated samples relative to DMSO-treated samples.
Error bars indicate standard deviations from triplicate samples. Asterisks in-
dicate levels were significantly different (P  0.001 by Student’s t test) from
similarly DMSO-treated samples.
FIG 3 DS-96 blocks attachment of C. trachomatis EB host cell surface. Two
representative L929 cells that were incubated with EBs were pretreated with
DS-96 (8 M) or mock treated (DMSO) for an hour at 4°C. Infected cultures
were thoroughly washed to remove unbound bacteria, fixed with methanol,
and stained with fluorescently labeled anti-MOMP (Chlamydia; green), Evan’s
blue (cytosol; red), and DAPI (nuclei; blue).
DS-96 Inhibits Chlamydia trachomatis Infection
June 2014 Volume 58 Number 6 aac.asm.org 3249
 on D
ecem









treated with DS-96, a high level of inhibition (95.3%) was main-
tained through centrifugation-assisted infection. Further studies
are needed to determine what postentry event(s) is perturbed by
DS-96, or if infectious EBs are inactivated after exposure to the
compound. Nevertheless, it is of interest that the bacteria were
unable to progress through the developmental cycle even when
the absorption was facilitated by centrifugation.
While C. trachomatis LGV strains can efficiently infect cultured
mammalian cells, non-LGV strains generally require centrifuga-
tion for efficient infection in cell culture. LGV serovar L2 is a
commonly used C. trachomatis laboratory strain due to the rela-
tive ease of cultivation and shorter developmental cycle. However,
Chlamydia trachomatis serovars D, E, and F are more clinically
relevant strains, since they are reported to be the most prevalent
urogenital serovars worldwide (40). With the data revealing that
the effect of DS-96 is maintained through centrifugation-assisted
inoculation, an inhibition experiment was performed with C. tra-
chomatis serovar D and the mouse pathogen C. muridarum, both
of which are typically infected using a centrifugation-assisted pro-
cedure. Greater than 80% inhibition of the bacterial growth was
observed for both C. trachomatis serovar D and C. muridarum at 4
M, a concentration lower than that needed for equivalent inhi-
bition of the C. trachomatis LGV strain (Fig. 6).
Treatment of EBs by DS-96 alters the binding of antibody
against Chlamydia LOS. Considering the rational design of the
compound, along with the structural similarities between E. coli
and Chlamydia lipid A, it is highly anticipated that the observed
inhibitory effect of DS-96 in Chlamydia infection is through the
interaction with LOS. In an attempt to demonstrate this interac-
tion, the immunofluorescent staining pattern of the bacteria by
monoclonal antibody specific to chlamydial LOS was examined by
confocal microscopy (Fig. 7). It was anticipated that binding of
DS-96 to LOS could alter the antibody-binding epitope on LOS
and consequently result in the absence of LOS staining. To per-
form this study, purified C. trachomatis EBs were pretreated with
DS-96 or mock treated with DMSO as a control and allowed to
adhere to the plastic bottom of a cell culture plate for an hour.
Following methanol fixation, samples were stained with monoclo-
nal antibody against LOS or MOMP as a control and counter-
stained with DAPI. When visualized by immunofluorescence mi-
FIG 4 Entry of C. trachomatis EBs into the host cell is inhibited by DS-96. C. trachomatis EBs were allowed to attach and enter host cells. Differential
immunofluorescent staining was performed 4 hpi to discriminate between the extracellular and internalized EBs. (A) Representative images of infected cells. Host
cell surface-associated EBs were labeled with anti-MOMP antibody (red) prior to cell permeabilization, and total EBs (intracellular plus extracellular) were
labeled with anti-Chlamydia antibody (green) after permeabilization. The inset shows the internalized bacteria (green) in a mock-treated sample and the
extracellular bacteria (yellow) in a DS-96-treated sample. (B) Percentage of EBs internalized relative to total EBs was quantified. The asterisk indicates that levels
measured were significantly different (P  0.001 by Student’s t test) from those of DMSO-treated samples.
FIG 5 Inhibition by DS-96 is maintained after centrifugation. Following pre-
treatment of EBs with DS-96 (8 M) or heparan sulfate (HS) for 1 h, infection
was performed with or without centrifugation (900  g for 1 h). Infected
cultures were fixed with methanol, immunofluorescently stained, and ana-
lyzed for inhibition of inclusion formation 24 hpi using iBAChIE (32). Error
bars indicate standard deviations from triplicate samples. The asterisk indi-
cates that levels measured were significantly different (P  0.001 by Student’s
t test) from those for DMSO-treated samples.
FIG 6 Inhibition of C. trachomatis serovar D and C. muridarum. Centrifuga-
tion-assisted infection was performed with C. trachomatis serovar D (A) and C.
muridarum (B) in the presence of various concentrations of DS-96 and quan-
tified 24 hpi using the automated enumeration method iBAChIE (32). Percent
inhibition was counted based on the number of inclusion-positive cells in
DS-96-treated samples relative to DMSO-treated samples. Error bars indicate
standard deviations from the triplicate samples. The asterisk indicates that
levels measured were significantly different (P  0.001 by Student’s t test) from
those for DMSO-treated samples.
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croscopy, anti-MOMP antibody stained the bacteria similarly to
DAPI staining in both control and DS-96-treated samples. In con-
trast, while anti-LOS staining was consistent with DAPI staining
in the control sample, staining by anti-LOS was completely absent
from the sample treated with DS-96. Although this does not pro-
vide direct evidence for an interaction of DS-96 with LOS, it sug-
gests that DS-96 treatment of Chlamydia results in altering or
possibly masking the epitope recognized by the anti-LOS antibody
used in this study.
The effect of phosphate on the activity of DS-96. HBSS is a
common buffer in Chlamydia infection in cell culture, and it was
used throughout this study. However, SPG generally has been ac-
cepted as a suitable transport and storage medium for Chlamydia.
More importantly, it is commonly used in animal challenge stud-
ies. Before considering challenge studies in an animal model, the
inhibition study was repeated using SPG in place of HBSS. Sur-
prisingly, a complete lack of inhibition by DS-96 (8 M) was
observed when the cell culture inhibition assay was repeated with
SPG (data not shown). To determine which component of SPG
(220 mM sucrose, 8.5 mM NaHPO4, 3.7 mM KH2PO4, 4.9 mM
L-glutamic acid) was accountable for the impairment of DS-96
activity against Chlamydia, each constituent was added separately
to HBSS, and the effect on DS-96 activity was observed in the cell
culture infection (Fig. 8). In the presence of sucrose or glutamic
acid, the inhibitory activity of DS-96 remained comparable to that
of the control (HBSS alone), resulting in a high level of inhibition.
In contrast, when NaHPO4 and KH2PO4 were added together to
HBSS, the level of infection was similar to that of the untreated
sample, indicating that the activity of DS-96 against Chlamydia
infection was impaired in the presence of these components. Con-
sidering that the molecular interaction between DS-96 and E. coli
LPS is expected to involve formation of salt bridges between the
two phosphates on lipid A and the amine groups on DS-96 (12,
13), it is reasonable to speculate that free phosphate from
NaHPO4 and KH2PO4 competitively interact with the amine for
the salt bridge formation essential for the activity of DS-96. Al-
though phosphate is commonly used in buffer solutions and is
present in HBSS, the concentration of phosphate is approximately
15 times higher in SPG than in HBSS, which suggests that the
phosphate component of the buffer, at high concentration, out-
competes lipid A for the interaction with DS-96. To assist in sup-
porting this possibility, the experiment was repeated using PBS,
which contains a phosphate concentration comparable to that of
SPG. The data revealed that PBS blocked the activity of DS-96
similarly to SPG, supporting that phosphate is the component
responsible for impairment of the activity of DS-96. Importantly,
this observation gives further evidence that DS-96 is indeed inter-
acting with Chlamydia lipid A in a manner similar to its interac-
tion with E. coli lipid A.
DISCUSSION
In search for an active component effective against Chlamydia
infection with potential to be considered for a vaginally delivered
microbicide, the LPS binding molecule DS-96 was examined for
inhibitory properties. Numerous observations within this study
support that DS-96 inhibits Chlamydia infection of cell culture. A
dose-dependent inhibition was observed with greater than 80%
protection at 8 M (Fig. 1B and C). Attachment to the host cell
appears to be the stage of infection where EBs were predominantly
inhibited by DS-96 treatment (Fig. 3), although entry and possibly
postentry events were also affected by the treatment (Fig. 4 and 5).
The possible effect on postentry events is highlighted by the inhi-
bition observed following centrifugation-assisted infection, which
is thought to override binding and entry mechanisms. This study
also provided indirect evidence for the specificity of DS-96 inter-
action with Chlamydia LOS, which was demonstrated by the ab-
sence of immunofluorescence detection of LOS following DS-96
treatment (Fig. 7), as well as the effect of high phosphate concen-
tration on DS-96 activity (Fig. 8), which is discussed further be-
FIG 7 Pretreatment of EBs with DS-96 results in reduction of anti-LOS stain-
ing. Purified EBs were treated with DS-96 (8 M) or DMSO and stained for
LOS (A) or MOMP (B) following methanol fixation. Samples were counter-
stained with DAPI to visualize the total number of bacteria.
FIG 8 Phosphate impairs activity of DS-96. The inhibition assay was performed with HBSS supplemented with each constituent of SPG. Samples were fixed with
methanol 24 hpi. Chlamydia was stained with anti-MOMP antibody (Chlamydia; green), and host cells were counterstained with DAPI (nuclei; blue) and Evan’s
blue (cytoplasm; red).
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low. Together, these data support that DS-96 is an effective inhib-
itor of Chlamydia infection, albeit within tissue culture cells. A
potential limitation for the clinical use of DS-96 was the observed
decrease in inhibitory capability (40%) when compound was
added at the same time as infection instead of as a pretreatment
(Fig. 2D). While this is of concern, cell toxicity prevented the
addition and evaluation of higher concentrations of DS-96 during
coincubation. This concern is tempered by observations in the
original animal studies evaluating the utility and toxicity of DS-96
for sepsis (12). During these studies, high micromolar (	500 M)
concentrations of DS-96 were employed and toxicity was not de-
tectable. This observation supports that higher concentrations of
DS-96 should be tolerated during combined treatment and infec-
tion in mice, possibly achieving much higher protection. How-
ever, it is important to point out that previous toxicity studies (12)
were not performed on mucosal surfaces, including vaginal expo-
sure, that will need to be performed before clinical application can
be considered.
In addition to the commonly used laboratory strain C. tracho-
matis LGV, we tested the activity of DS-96 against C. trachomatis
serovar D and C. muridarum (Fig. 6) as one of the most clinically
prevalent serovars (41–43) and a mouse pathogen, respectively.
Interestingly, lower doses of DS-96 were as effective against these
strains as they were against LGV, indicating higher susceptibility.
Although further studies, including animal challenge, will be re-
quired to provide more evidence, these observations suggest that
serovar D and C. muridarum have greater requirements for LOS in
their infectivity than serovar LGV. Considering that the structure
of the lipid A glucosamine backbone is well conserved throughout
Gram-negative bacteria (44), it is highly unlikely that the affinity
of DS-96 toward lipid A varies among Chlamydia spp. However,
the requirements for LOS in the establishment of productive in-
fection may be different between various serovars and species of
Chlamydia due to the differences in their tissue tropisms. The idea
of differential requirements for infectivity between serovars and
various species of Chlamydia is well accepted, especially for the
specific ligand-receptor interactions during bacterial attachment
and entry (27). In support of our findings, it has been reported
that C. trachomatis serovar E was more susceptible to various LOS
inhibitors than serovar LGV in vitro (19). Clearly, it will be critical
to evaluate the efficacy of DS-96, and further developed chemical
analogs, using clinically relevant serovars of Chlamydia in animal
challenge studies.
To be a vaginal microbicide, the candidate inhibitors should
have the ability to specifically target vaginal pathogens while hav-
ing little deleterious effect on the normal vaginal flora. While total
genomic analyses are providing a new appreciation of the vaginal
microbial diversity, vaginal microbiota of healthy women typi-
cally is dominated by the hydrogen peroxide-producing Gram-
positive Lactobacillus species, which is essential in maintaining
vaginal homeostasis and providing the natural defense against
pathogenic organisms (45–47). In this aspect, DS-96 designed
specifically to target a virulence factor unique to Gram-negative
bacteria has the potential to be effective against Neisseria gonor-
rhea, in addition to C. trachomatis, while having limited adverse
effects on the normal vaginal flora dominated by Gram-positive
Lactobacillus spp. While the application and utility of DS-96 for
these infections is an encouraging possibility, a relatively high per-
centage (30%) of women have bacterial vaginosis that can be
dominated by LOS/LPS-containing Gram-negative bacteria. This
high concentration of lipid A target could substantially decrease
the availability of DS-96 introduced to prevent Chlamydia and
Neisseria infections in this portion of the female population. Fur-
ther complicating the challenge is the higher susceptibility of
women with bacterial vaginosis to sexually transmitted diseases.
An alternative view is that DS-96, or future chemical analogs,
could be an effective addition in vaginal microbicides to treat bac-
terial vaginosis locally and assist in enhancing the balance of Lac-
tobacillus. Future studies are certainly required to ascertain the
clinical utility of DS-96 with these approaches.
Moreover, DS-96 not only is an attractive microbicide candi-
date for Gram-negative vaginal pathogens but also served in this
study as a chemical biology tool to examine a role for LOS in
Chlamydia biology. Despite the recent major advances in genetic
systems (48–53), routine genetic manipulation of Chlamydia with
classic techniques remains challenging. The use of inhibitors tar-
geting specific virulence factors can substitute to facilitate the
studies of this nature. Our data demonstrated that both attach-
ment and entry processes of C. trachomatis were impaired in the
presence of DS-96, which may reflect a role of LOS in early events
during the developmental cycle, specifically binding and entry.
Other studies have used Chlamydia LOS as a target for disruption
of the developmental cycle, and various functions have been pro-
posed (19, 30). Fadel and Eley postulated a general role of LOS in
Chlamydia infectivity (19). They demonstrated that infection of
human epithelial cells by C. trachomatis serovar LGV and serovar
E was inhibited in the presence of purified LOS, PMB, antibody
against C. trachomatis LOS, and synthetic Kdo (19). Similar to our
study, a role of Chlamydia LOS in adherence was also suggested
(19). More recently, Nguyen et al. examined the biological signif-
icance of Chlamydia LOS using LOS biosynthesis inhibitors (LpxC
inhibitors) and proposed a crucial role of LOS in proper morpho-
logical transition of RBs to EBs (30). Their study revealed that a
decreased number of progeny EBs was generated in the presence
of LpxC inhibitors (30). They also reported that OmcB, a mem-
brane protein specific to the EB surface, was poorly expressed in
the absence of LOS (30). Our study extended the possible role of
LOS to chlamydial attachment and entry steps, although the in-
hibitory effect may be indirect. Similar to the effect of LpxC inhib-
itors on the expression of OmcB, the interaction between DS-96
and LOS may disrupt other key surface molecules required for
binding and entry. For instance, Chlamydia is known to promote
entry into host cells by inducing host cell actin polymerization via
injection of the type 3 secretion effector Tarp (54, 55). Consider-
ing the findings of Nguyen et al., it is possible that DS-96 treat-
ment of LOS results in functional disruptions of other outer mem-
brane surface molecules, such as type 3 secretion systems.
One of the unexpected but potentially revealing observations
of this study was the blocking of DS-96 inhibitory effect by high
phosphate concentrations. With an expectation to examine the
efficacy of DS-96 in vivo in the near future, the inhibition experi-
ments were repeated with SPG, a buffer commonly used in animal
challenge models. To our surprise, the inhibitory effect by DS-96
was reversed in the presence of SPG (data not shown), and it was
determined that phosphate was solely responsible for blocking the
inhibitory activity of DS-96 (Fig. 8). The observation was further
confirmed when PBS, a buffer containing phosphate at a concen-
tration similar to that of SPG, also blocked DS-96 activity. This
observation was particularly intriguing considering the molecular
design of DS-96. Sil et al. reported the central pharmacophores,
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which have been experimentally tested and defined for optimal
recognition and neutralization of lipid A (12, 56). These pharma-
cophore properties include (i) two protonatable cationic func-
tions 14 Å apart that are necessary for simultaneous ionic inter-
actions with the negatively charged phosphates on lipid A and (ii)
appropriately positioned hydrophobic groups. Given that the
ionic interaction with the phosphates on lipid A is a requisite for
the compound activity, it is plausible to reason that deactivation of
DS-96 is a result of the free phosphate in the buffer solution com-
petitively binding to the amine groups on DS-96. This observation
supports, albeit indirectly, the specificity of the interaction be-
tween DS-96 and Chlamydia lipid A. Furthermore, with the ulti-
mate goal of developing vaginally delivered microbicide, formu-
lation is a critical factor to be considered for the stability of the
compound in the vaginal environment, where various factors may
influence the activity of the compound. Deactivation of DS-96 by
phosphate observed in this assay emphasizes the importance of
compound formulation, especially given that the concentrations
of inorganic ions, including phosphate, in the vaginal lumen are
unclear (57). Nonetheless, considering its effectiveness against C.
trachomatis infection in vitro along with its demonstrated low tox-
icity in a mouse model, it is expected that DS-96 will perform well
as a microbicide candidate compound in future animal model
studies.
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